<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04726839</url>
  </required_header>
  <id_info>
    <org_study_id>APHP200188</org_study_id>
    <nct_id>NCT04726839</nct_id>
  </id_info>
  <brief_title>Biomarkers algOrithm for strOke diagnoSis and Treatment Resistance Prediction</brief_title>
  <acronym>BOOST</acronym>
  <official_title>Biomarkers algOrithm for strOke diagnoSis and Treatment Resistance Prediction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Triage of acute ischemic stroke (AIS) patients is critical, to decrease time to treatment,&#xD;
      and improve functional outcome. The therapeutic standard of care for AIS consecutive to large&#xD;
      vessel occlusion (LVO) is the association of intravenous (IV) alteplase administration and&#xD;
      mechanical thrombectomy (MT). However, there are limited places where MT can be performed.&#xD;
      Therefore, there is a need for innovative tools to identify, in the ambulance, patients with&#xD;
      LVO that require MT. Sending the patients at the right, avoiding futile stops (i.e. in places&#xD;
      where MT is not available), is definitively a strategy that saves time.&#xD;
&#xD;
      There is currently no biomarker nor Point Of Care (POC) Lab Testing to solve this issue and&#xD;
      clinical scoring methods such as the NIHSS have a low accuracy rate to detect LVO. The&#xD;
      relevance of blood biomarkers for LVO diagnosis and therapeutic decisions needs to be&#xD;
      confirmed for effective triage in the setting of AIS with LVO, which represent 30% of all&#xD;
      AIS.&#xD;
&#xD;
      The main objective of our study is to determine diagnostic performances of a panel of&#xD;
      selected blood biomarkers to identify patients with AIS consecutive to LVO among those with&#xD;
      stroke suspicion, within 24 hours of stroke symptom's onset before brain imaging.&#xD;
&#xD;
      This could facilitate the triage of patients with LVO refractory to thrombolysis treatment,&#xD;
      who may benefit most from MT.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 12, 2021</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnosis by the selected panel of blood biomarkers of the LVO presence eligible for MT</measure>
    <time_frame>within 24 hours following inclusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Discrimination by the selected panel of blood biomarkers of LVO from small strokes, and AIS from hemorrhagic strokes and stroke mimics</measure>
    <time_frame>within 24 hours following inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>reperfusion therapy resistance (i.e. IV thrombolysis, MT)</measure>
    <time_frame>within 24 hours following inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardio-embolic origin</measure>
    <time_frame>at 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early neurological improvement</measure>
    <time_frame>at day 1 after inclusion</time_frame>
    <description>Early neurological improvement will be assessed by NIHSS. Early neurological improvement will be defined as decrease of 8 points in the NIHSS or a NIHSS 0-1 within 24h for LVO confirmed patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional outcome</measure>
    <time_frame>at day 90 after inclusion</time_frame>
    <description>Functional outcome will be assessed by modified Rankin Scale (mRS); It consists of a single item, with 6 levels of disability. 0 corresponding to no disability, and five to severe disability.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">3946</enrollment>
  <condition>Stroke, Ischemic</condition>
  <condition>Large Vessel Occlusion</condition>
  <arm_group>
    <arm_group_label>Stroke suspicion</arm_group_label>
    <description>Patients with stroke suspicion within 24 hours of stroke's symptoms</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of care for stroke management and evaluation of functionnal outcome at 3 months</intervention_name>
    <description>Additional tubes at inclusion (maximum 13 mL) Collection of the mRS data during a routine visit if planned at 3 months +/-15 days or, if not during a specific research phone call at 3 months</description>
    <arm_group_label>Stroke suspicion</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with stroke suspicion within 24 hours of stroke's symptoms&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Symptoms consistent with stroke &lt;24 hours&#xD;
&#xD;
          -  Adult patients ≥ 18 years old&#xD;
&#xD;
          -  Non opposition of the patient or his/her relatives to the research (emergency&#xD;
             inclusion procedure)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient under guardianship or curatorship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Mikael Mazighi</last_name>
    <phone>+331 48 03 67 03</phone>
    <email>mikael.mazighi@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Matthieu Resche-Rigon</last_name>
    <email>matthieu.resche-rigon@u-paris.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department Neurology Caen Hospital</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emmanuel Touzé</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lariboisière</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikael Mazighi, Pr</last_name>
      <email>mikael.mazighi@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rothschild Foundation Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mazighi Mikael</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Foch</name>
      <address>
        <city>Suresnes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bertrand Lapergue</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 24, 2021</study_first_submitted>
  <study_first_submitted_qc>January 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2021</study_first_posted>
  <last_update_submitted>June 23, 2021</last_update_submitted>
  <last_update_submitted_qc>June 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

